MacroGenics axes ADC drug following Phase II failure in prostate cancer
MacroGenics is axing the development of one of its antibody-drug conjugates (ADC) after it flopped in a Phase II study …
Post
-
-
iECURE gene therapy data suggests partial restoration of functional OTC
Gene editing company iECURE has said data from its Phase I/II ornithine transcarbamylase (OTC) deficiency trial could suggest partial restoration …
-
Icon integrates Medidata’s Clinical Data Studio into clinical studies
Clinical research organisation (CRO) Icon has begun the integration of Medidata Clinical Data Studio into its clinical studies. This development makes …
-
Mixed data results for two Monte Rosa molecular glue degraders
Monte Rosa Therapeutics has seen good news for one of its molecular glue degradation candidates and bad news for another …
-
Global funding cuts reversing decades of tuberculosis progress, WHO says
Ahead of World Tuberculosis Day on 24 March, the World Health Organization (WHO) has said that cuts in global funding …
-
IGC adds new clinical site in Canada for Alzheimer’s agitation therapy trial
IGC Pharma has added Hamilton Health Sciences (HHS) in Canada as a new clinical site for its ongoing, randomised Phase …
-
Potential impacts of the US withdrawal from the WHO on clinical trials globally
The US is set to sever its relationship with the World Health Organization (WHO) as President Donald Trump has issued …
-
iOnctura doses first subject in Phase II uveal melanoma treatment trial
iOnctura has dosed the first subject in the open-label Phase II OCULE-01 trial of oral roginolisib in individuals with rare …
-
Neurocrine Biosciences debuts new data for effectiveness of Ingrezza
Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses …
-
Omnipod 5 improves glycaemic levels in people transitioning from daily injections
Individuals with type 1 diabetes (T1D) have demonstrated improvements in glycaemic control after transitioning away from daily insulin injections to …
-
NACE to launch trial in Australia for young people with hay fever
The National Allergy Centre of Excellence (NACE), hosted at Murdoch Children's Research Institute (MCRI), has collaborated with 17 Australian general …
-
Funding drought: how can biotech and biopharma keep trials running?
It’s widely known in the industry that private investment in biotech and biopharma has been down in recent years. Whilst …
-
Roche’s discontinued Alzheimer’s drug shows signs of preventing onset
Roche’s discontinued Alzheimer’s disease drug has shown signs that it could prevent onset of the disease. The Phase II/III Knight Family …
-
Novartis reports Phase III efficacy and safety outcomes of SMA treatment
Novartis has reported positive efficacy and safety outcomes from its Phase III clinical programme for OAV101 IT (onasemnogene abeparvovec), an …
-
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old
Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study (NCT05693142), which is examining …
